|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: JAGN1 |
Gene summary for JAGN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | JAGN1 | Gene ID | 84522 |
| Gene name | jagunal homolog 1 | |
| Gene Alias | GL009 | |
| Cytomap | 3p25.3 | |
| Gene Type | protein-coding | GO ID | GO:0001678 | UniProtAcc | Q8N5M9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84522 | JAGN1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.29e-03 | 1.44e-01 | 0.0155 |
| 84522 | JAGN1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.18e-05 | 2.30e-01 | -0.1808 |
| 84522 | JAGN1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.65e-05 | 3.31e-01 | -0.0811 |
| 84522 | JAGN1 | HTA11_347_2000001011 | Human | Colorectum | AD | 8.50e-17 | 3.64e-01 | -0.1954 |
| 84522 | JAGN1 | HTA11_411_2000001011 | Human | Colorectum | SER | 7.13e-06 | 5.81e-01 | -0.2602 |
| 84522 | JAGN1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 7.88e-06 | 4.60e-01 | -0.2196 |
| 84522 | JAGN1 | HTA11_83_2000001011 | Human | Colorectum | SER | 4.35e-04 | 2.64e-01 | -0.1526 |
| 84522 | JAGN1 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.77e-05 | 2.16e-01 | -0.1464 |
| 84522 | JAGN1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.17e-08 | 3.18e-01 | -0.059 |
| 84522 | JAGN1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 7.64e-03 | 2.44e-01 | -0.1706 |
| 84522 | JAGN1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.39e-05 | 3.23e-01 | -0.2061 |
| 84522 | JAGN1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.71e-02 | 4.21e-01 | -0.1462 |
| 84522 | JAGN1 | HTA11_866_3004761011 | Human | Colorectum | AD | 8.19e-09 | 2.68e-01 | 0.096 |
| 84522 | JAGN1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.14e-04 | 3.07e-01 | 0.0528 |
| 84522 | JAGN1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.36e-10 | 2.86e-01 | 0.0674 |
| 84522 | JAGN1 | HTA11_7469_2000001011 | Human | Colorectum | AD | 2.07e-05 | 5.48e-01 | -0.0124 |
| 84522 | JAGN1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.21e-10 | 2.99e-01 | 0.294 |
| 84522 | JAGN1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.06e-06 | 3.20e-01 | 0.281 |
| 84522 | JAGN1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.22e-19 | 5.40e-01 | 0.3859 |
| 84522 | JAGN1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.86e-09 | 2.77e-01 | 0.3005 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0009743 | Colorectum | AD | response to carbohydrate | 86/3918 | 253/18723 | 8.43e-07 | 2.90e-05 | 86 |
| GO:0030099 | Colorectum | AD | myeloid cell differentiation | 119/3918 | 381/18723 | 1.24e-06 | 4.01e-05 | 119 |
| GO:0034284 | Colorectum | AD | response to monosaccharide | 76/3918 | 225/18723 | 4.64e-06 | 1.23e-04 | 76 |
| GO:0033500 | Colorectum | AD | carbohydrate homeostasis | 84/3918 | 259/18723 | 9.10e-06 | 2.15e-04 | 84 |
| GO:0009746 | Colorectum | AD | response to hexose | 73/3918 | 219/18723 | 1.20e-05 | 2.65e-04 | 73 |
| GO:0009749 | Colorectum | AD | response to glucose | 71/3918 | 212/18723 | 1.31e-05 | 2.85e-04 | 71 |
| GO:0042593 | Colorectum | AD | glucose homeostasis | 83/3918 | 258/18723 | 1.44e-05 | 3.11e-04 | 83 |
| GO:0001678 | Colorectum | AD | cellular glucose homeostasis | 60/3918 | 172/18723 | 1.49e-05 | 3.18e-04 | 60 |
| GO:0071322 | Colorectum | AD | cellular response to carbohydrate stimulus | 56/3918 | 163/18723 | 4.61e-05 | 7.97e-04 | 56 |
| GO:0050708 | Colorectum | AD | regulation of protein secretion | 83/3918 | 268/18723 | 6.59e-05 | 1.07e-03 | 83 |
| GO:0071333 | Colorectum | AD | cellular response to glucose stimulus | 52/3918 | 151/18723 | 7.88e-05 | 1.25e-03 | 52 |
| GO:0009306 | Colorectum | AD | protein secretion | 105/3918 | 359/18723 | 1.05e-04 | 1.57e-03 | 105 |
| GO:0071331 | Colorectum | AD | cellular response to hexose stimulus | 52/3918 | 153/18723 | 1.16e-04 | 1.71e-03 | 52 |
| GO:0035592 | Colorectum | AD | establishment of protein localization to extracellular region | 105/3918 | 360/18723 | 1.18e-04 | 1.73e-03 | 105 |
| GO:0071326 | Colorectum | AD | cellular response to monosaccharide stimulus | 52/3918 | 154/18723 | 1.40e-04 | 1.98e-03 | 52 |
| GO:0071692 | Colorectum | AD | protein localization to extracellular region | 106/3918 | 368/18723 | 1.86e-04 | 2.49e-03 | 106 |
| GO:0050796 | Colorectum | AD | regulation of insulin secretion | 54/3918 | 165/18723 | 2.60e-04 | 3.25e-03 | 54 |
| GO:0030073 | Colorectum | AD | insulin secretion | 61/3918 | 195/18723 | 4.28e-04 | 4.81e-03 | 61 |
| GO:0061178 | Colorectum | AD | regulation of insulin secretion involved in cellular response to glucose stimulus | 25/3918 | 64/18723 | 6.98e-04 | 7.10e-03 | 25 |
| GO:0015833 | Colorectum | AD | peptide transport | 77/3918 | 264/18723 | 8.90e-04 | 8.60e-03 | 77 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| JAGN1 | insertion | In_Frame_Ins | novel | c.172_173insAAGTCTCACTCTGCACTCTGTCCCCCA | p.Gly58delinsGluValSerLeuCysThrLeuSerProArg | p.G58delinsEVSLCTLSPR | Q8N5M9 | protein_coding | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR | ||
| JAGN1 | SNV | Missense_Mutation | novel | c.540N>T | p.Lys180Asn | p.K180N | Q8N5M9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.977) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| JAGN1 | SNV | Missense_Mutation | novel | c.287A>C | p.Asn96Thr | p.N96T | Q8N5M9 | protein_coding | tolerated(0.08) | benign(0.03) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| JAGN1 | SNV | Missense_Mutation | rs542419840 | c.392G>A | p.Arg131His | p.R131H | Q8N5M9 | protein_coding | deleterious(0.02) | possibly_damaging(0.782) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| JAGN1 | SNV | Missense_Mutation | c.410N>A | p.Arg137His | p.R137H | Q8N5M9 | protein_coding | deleterious(0.03) | benign(0.015) | TCGA-BS-A0UM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| JAGN1 | SNV | Missense_Mutation | c.490N>C | p.Tyr164His | p.Y164H | Q8N5M9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-RC-A7SK-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| JAGN1 | SNV | Missense_Mutation | novel | c.43N>G | p.Ser15Gly | p.S15G | Q8N5M9 | protein_coding | deleterious(0.04) | benign(0.146) | TCGA-34-A5IX-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| JAGN1 | SNV | Missense_Mutation | c.206N>A | p.Ala69Asp | p.A69D | Q8N5M9 | protein_coding | tolerated(0.26) | benign(0.255) | TCGA-66-2759-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | CR | |
| JAGN1 | SNV | Missense_Mutation | novel | c.162G>C | p.Lys54Asn | p.K54N | Q8N5M9 | protein_coding | deleterious(0.01) | benign(0.038) | TCGA-85-8354-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| JAGN1 | insertion | In_Frame_Ins | novel | c.500_501insATACGG | p.Lys167_Lys168insTyrGly | p.K167_K168insYG | Q8N5M9 | protein_coding | TCGA-CN-A497-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |